Impact of Early Natural Killer Cell Reconstitution on the Outcomes of T Cell-Replete Allogeneic Hematopoietic Stem Cell Transplantation

References

• Xue YJ, Suo P, Huang XJ, et al. Superior survival of unmanipulated haploidentical haematopoietic stem cell transplantation compared with intensive chemotherapy as post-remission treatment for children with very high-risk Philadelphia chromosome negative B-cell acute lymphoblastic leukaemia in first complete remission. Brit J Haematol. 2019;188:757–767. doi:10.1111/bjh.16226
   PubMed Web of Science ®Google Scholar
• Kleinschmidt K, Lv M, Yanir A, et al. T-cell-replete versus ex vivo T-cell-depleted haploidentical haematopoietic stem cell transplantation in children with acute lymphoblastic leukaemia and other haematological malignancies. Front Pediatr. 2021;9:794541. doi:10.3389/fped.2021.794541
   PubMed Web of Science ®Google Scholar
• Ogonek J, Kralj Juric M, Ghimire S, et al. Immune reconstitution after allogeneic hematopoietic stem cell transplantation. Front Immunol. 2016;7:507. doi:10.3389/fimmu.2016.00507
   PubMed Web of Science ®Google Scholar
• Gill S, Olson JA, Negrin RS. Natural killer cells in allogeneic transplantation: effect on engraftment, graft- versus-tumor, and graft-versus-host responses. Biol Blood Marrow Transplant. 2009;15:765–776. doi:10.1016/j.bbmt.2009.01.019
   PubMed Web of Science ®Google Scholar
• Locatelli F, Merli P, Rutella S. At the bedside: innate immunity as an immunotherapy tool for hematological malignancies. J Leukoc Biol. 2013;94:1141–1157. doi:10.1189/jlb.0613343
   PubMed Web of Science ®Google Scholar
• Zaghi E, Calvi M, Di Vito C, Mavilio D. Innate immune responses in the outcome of haploidentical hematopoietic stem cell transplantation to cure hematologic malignancies. Front Immunol. 2019;10:2794. doi:10.3389/fimmu.2019.02794
   PubMed Web of Science ®Google Scholar
• Anfossi N, André P, Guia S, et al. Human NK cell education by inhibitory receptors for MHC class I. Immunity. 2006;25:331–342. doi:10.1016/j.immuni.2006.06.013
   PubMed Web of Science ®Google Scholar
• Savani BN, Mielke S, Adams S, et al. Rapid natural killer cell recovery determines outcome after T-cell-depleted HLA-identical stem cell transplantation in patients with myeloid leukemias but not with acute lymphoblastic leukemia. Leukemia. 2007;21:2145–2152. doi:10.1038/sj.leu.2404892
   PubMed Web of Science ®Google Scholar
• Lv M, Chang YJ, Huang XJ. Update of the “Beijing Protocol” haplo-identical hematopoietic stem cell transplantation. Bone Marrow Transpl. 2019;54:703–707. doi:10.1038/s41409-019-0605-2
   PubMedGoogle Scholar
• Huang XJ, Liu DH, Liu KY, et al. Haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion for the treatment of hematological malignancies. Bone Marrow Transpl. 2006;38:291–297. doi:10.1038/sj.bmt.1705445
   PubMed Web of Science ®Google Scholar
• Chiossone L, Vitale C, Cottalasso F, et al. Molecular analysis of the methylprednisolone-mediated inhibition of NK-cell function: evidence for different susceptibility of IL-2- versus IL-15-activated NK cells. Blood. 2007;109:3767–3775. doi:10.1182/blood-2006-07-037846
   PubMed Web of Science ®Google Scholar
• Pradier A, Papaserafeim M, Li N, et al. Small-molecule immunosuppressive drugs and therapeutic immunoglobulins differentially inhibit NK cell effector functions in vitro. Front Immunol. 2019;10:556. doi:10.3389/fimmu.2019.00556
   PubMed Web of Science ®Google Scholar
• Vivier E, Ugolini S. Natural killer cells: from basic research to treatments. Front Immunol. 2011;2:18. doi:10.3389/fimmu.2011.00018
   PubMed Web of Science ®Google Scholar
• Cooley S, Parham P, Miller JS. Strategies to activate NK cells to prevent relapse and induce remission following hematopoietic stem cell transplantation. Blood. 2018;131:1053–1062. doi:10.1182/blood-2017-08-752170
   PubMed Web of Science ®Google Scholar
• Hüber CM, Doisne JM, Colucci F. IL-12/15/18-preactivated NK cells suppress GvHD in a mouse model of mismatched hematopoietic cell transplantation. Eur J Immunol. 2015;45:1727–1735. doi:10.1002/eji.201445200
   PubMed Web of Science ®Google Scholar
• Yamamoto W, Ogusa E, Matsumoto K, Maruta A, Ishigatsubo Y, Kanamori H. Recovery of natural killer cells and prognosis after cord blood transplantation. Leuk Res. 2013;37:1522–1526. doi:10.1016/j.leukres.2013.09.005
   PubMed Web of Science ®Google Scholar
• Pfeiffer MM, Feuchtinger T, Teltschik HM, et al. Reconstitution of natural killer cell receptors influences natural killer activity and relapse rate after haploidentical transplantation of T- and B-cell depleted grafts in children. Haematologica. 2010;95:1381–1388. doi:10.3324/haematol.2009.021121
   PubMed Web of Science ®Google Scholar
• Minculescu L, Marquart HV, Friis LS, et al. Early natural killer cell reconstitution predicts overall survival in T cell-replete allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2016;22:2187–2193. doi:10.1016/j.bbmt.2016.09.006
   PubMedGoogle Scholar
• Gao F, Ye Y, Gao Y, Huang H, Zhao Y. Influence of KIR and NK cell reconstitution in the outcomes of hematopoietic stem cell transplantation. Front Immunol. 2020;11:2022. doi:10.3389/fimmu.2020.02022
   PubMed Web of Science ®Google Scholar
• Ullah MA, Hill GR, Tey SK. Functional reconstitution of natural killer cells in allogeneic hematopoietic stem cell transplantation. Front Immunol. 2016;7:144. doi:10.3389/fimmu.2016.00144
   PubMed Web of Science ®Google Scholar
• Zhao F, Shi Y, Chen X, et al. Higher dose of CD34(+) cells promotes early reconstitution of natural killer cells and is associated with better outcomes after unmanipulated hematopoietic stem cell transplantation for myeloid malignancies. Transplant Cell Ther. 2022;28:589.e581–589.e510. doi:10.1016/j.jtct.2022.06.007
   Google Scholar
• Bühlmann L, Buser AS, Cantoni N, et al. Lymphocyte subset recovery and outcome after T-cell replete allogeneic hematopoietic SCT. Bone Marrow Transplant. 2011;46:1357–1362. doi:10.1038/bmt.2010.306
   PubMed Web of Science ®Google Scholar
• Ball LM, Egeler RM. Acute GvHD: pathogenesis and classification. Bone Marrow Transplant. 2008;41:S58–64. doi:10.1038/bmt.2008.56
   PubMed Web of Science ®Google Scholar
• Vacca P, Montaldo E, Croxatto D, et al. NK cells and other innate lymphoid cells in hematopoietic stem cell transplantation. Front Immunol. 2016;7:188. doi:10.3389/fimmu.2016.00188
   PubMed Web of Science ®Google Scholar
• Olson JA, Leveson-Gower DB, Gill S, Baker J, Beilhack A, Negrin RS. NK cells mediate reduction of GVHD by inhibiting activated, alloreactive T cells while retaining GVT effects. Blood. 2010;115:4293–4301. doi:10.1182/blood-2009-05-222190
   PubMed Web of Science ®Google Scholar
• Ciurea SO, Schafer JR, Bassett R, et al. Phase 1 clinical trial using mbIL21 ex vivo-expanded donor-derived NK cells after haploidentical transplantation. Blood. 2017;130:1857–1868. doi:10.1182/blood-2017-05-785659
   PubMed Web of Science ®Google Scholar
• Fujisaki H, Kakuda H, Shimasaki N, et al. Expansion of highly cytotoxic human natural killer cells for cancer cell therapy. Cancer Res. 2009;69:4010–4017. doi:10.1158/0008-5472.can-08-3712
   PubMed Web of Science ®Google Scholar
• Muntasell A, Ochoa MC, Cordeiro L, et al. Targeting NK-cell checkpoints for cancer immunotherapy. Curr Opin Immunol. 2017;45:73–81. doi:10.1016/j.coi.2017.01.003
   PubMed Web of Science ®Google Scholar
• Romee R, Rosario M, Berrien-Elliott MM, et al. Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia. Sci Transl Med. 2016;8:357ra123. doi:10.1126/scitranslmed.aaf2341
   PubMed Web of Science ®Google Scholar
• Ullrich E, Salzmann-Manrique E, Bakhtiar S, et al. Relation between acute GVHD and NK cell subset reconstitution following allogeneic stem cell transplantation. Front Immunol. 2016;7:595. doi:10.3389/fimmu.2016.00595
   PubMed Web of Science ®Google Scholar
• Hu LJ, Zhao XY, Yu XX, et al. Quantity and quality reconstitution of NKG2A(+) natural killer cells are associated with graft-versus-host disease after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2019;25:1–11. doi:10.1016/j.bbmt.2018.08.008
   PubMedGoogle Scholar
• Aktas E, Kucuksezer UC, Bilgic S, Erten G, Deniz G. Relationship between CD107a expression and cytotoxic activity. Cell Immunol. 2009;254:149–154. doi:10.1016/j.cellimm.2008.08.007
   PubMed Web of Science ®Google Scholar
• Alter G, Malenfant JM, Altfeld M. CD107a as a functional marker for the identification of natural killer cell activity. J Immunol Methods. 2004;294:15–22. doi:10.1016/j.jim.2004.08.008
   PubMed Web of Science ®Google Scholar
• Shah NN, Baird K, Delbrook CP, et al. Acute GVHD in patients receiving IL-15/4-1BBL activated NK cells following T-cell-depleted stem cell transplantation. Blood. 2015;125:784–792. doi:10.1182/blood-2014-07-592881
   PubMed Web of Science ®Google Scholar
• Meinhardt K, Kroeger I, Bauer R, et al. Identification and characterization of the specific murine NK cell subset supporting graft-versus-leukemia- and reducing graft-versus-host-effects. Oncoimmunology. 2015;4:e981483. doi:10.4161/2162402x.2014.981483
   PubMed Web of Science ®Google Scholar
• Kim SY, Lee H, Han MS, et al. Post-transplantation natural killer cell count: a predictor of acute graft-versus-host disease and survival outcomes after allogeneic hematopoietic stem cell transplantation. Clin Lymphoma Myeloma Leuk. 2016;16:527–535.e522. doi:10.1016/j.clml.2016.06.013
   PubMed Web of Science ®Google Scholar
• Kheav VD, Busson M, Scieux C, et al. Favorable impact of natural killer cell reconstitution on chronic graft-versus-host disease and cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation. Haematologica. 2014;99:1860–1867. doi:10.3324/haematol.2014.108407
   PubMed Web of Science ®Google Scholar
• Ljungman P, Boeckh M, Hirsch HH, et al. Definitions of cytomegalovirus infection and disease in transplant patients for use in clinical trials. Clin Infect Dis. 2017;64:87–91. doi:10.1093/cid/ciw668
   PubMed Web of Science ®Google Scholar
• Cho SY, Lee DG, Kim HJ. Cytomegalovirus infections after hematopoietic stem cell transplantation: current status and future immunotherapy. Int J Mol Sci. 2019;20:2666. doi:10.3390/ijms20112666
   PubMed Web of Science ®Google Scholar
• Ando T, Suzuki T, Ishiyama Y, et al. Impact of cytomegalovirus reactivation and natural killer reconstitution on outcomes after allogeneic hematopoietic stem cell transplantation: a single-center analysis. Biol Blood Marrow Transplant. 2020;26:171–177. doi:10.1016/j.bbmt.2019.09.028
   PubMed Web of Science ®Google Scholar
• Muccio L, Falco M, Bertaina A, et al. Late development of FcεRγ(neg) adaptive natural killer cells upon human cytomegalovirus reactivation in umbilical cord blood transplantation recipients. Front Immunol. 2018;9:1050. doi:10.3389/fimmu.2018.01050
   PubMed Web of Science ®Google Scholar
• Adams NM, Geary CD, Santosa EK, et al. Cytomegalovirus infection drives avidity selection of natural killer cells. Immunity. 2019;50:1381–1390.e1385. doi:10.1016/j.immuni.2019.04.009
   PubMed Web of Science ®Google Scholar
• Park KH, Ryu JH, Bae H, et al. Delayed NK cell reconstitution and reduced NK activity increased the risks of CMV disease in allogeneic-hematopoietic stem cell transplantation. Int J Mol Sci. 2020;21. doi:10.3390/ijms21103663
   Web of Science ®Google Scholar
• Zhao XY, Luo XY, Yu XX, et al. Recipient-donor KIR ligand matching prevents CMV reactivation post-haploidentical T cell-replete transplantation. Br J Haematol. 2017;177:766–781. doi:10.1111/bjh.14622
   PubMed Web of Science ®Google Scholar
• Pical-Izard C, Crocchiolo R, Granjeaud S, et al. Reconstitution of natural killer cells in HLA-matched HSCT after reduced-intensity conditioning: impact on clinical outcome. Biol Blood Marrow Transplant. 2015;21:429–439. doi:10.1016/j.bbmt.2014.11.681
   PubMedGoogle Scholar
• Park BG, Park CJ, Jang S, et al. Reconstitution of lymphocyte subpopulations after hematopoietic stem cell transplantation: comparison of hematologic malignancies and donor types in event-free patients. Leuk Res. 2015;39:1334–1341. doi:10.1016/j.leukres.2015.09.010
   PubMed Web of Science ®Google Scholar
• Ciurea SO, Mulanovich V, Saliba RM, et al. Improved early outcomes using a T cell replete graft compared with T cell depleted haploidentical hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2012;18:1835–1844. doi:10.1016/j.bbmt.2012.07.003
   PubMed Web of Science ®Google Scholar
• Eissens DN, Schaap NP, Preijers FW, et al. CD3+/CD19+-depleted grafts in HLA-matched allogeneic peripheral blood stem cell transplantation lead to early NK cell cytolytic responses and reduced inhibitory activity of NKG2A. Leukemia. 2010;24:583–591. doi:10.1038/leu.2009.269
   PubMed Web of Science ®Google Scholar
• Cooley S, McCullar V, Wangen R, et al. KIR reconstitution is altered by T cells in the graft and correlates with clinical outcomes after unrelated donor transplantation. Blood. 2005;106:4370–4376. doi:10.1182/blood-2005-04-1644
   PubMed Web of Science ®Google Scholar
• Bosch M, Dhadda M, Hoegh-Petersen M, et al. Immune reconstitution after anti-thymocyte globulin-conditioned hematopoietic cell transplantation. Cytotherapy. 2012;14:1258–1275. doi:10.3109/14653249.2012.715243
   PubMed Web of Science ®Google Scholar
• Servais S, Menten-Dedoyart C, Beguin Y, et al. Impact of pre-transplant Anti-T Cell Globulin (ATG) on immune recovery after myeloablative allogeneic peripheral blood stem cell transplantation. PLoS One. 2015;10:e0130026. doi:10.1371/journal.pone.0130026
   PubMed Web of Science ®Google Scholar
• Retière C, Willem C, Guillaume T, et al. Impact on early outcomes and immune reconstitution of high-dose post-transplant cyclophosphamide vs anti-thymocyte globulin after reduced intensity conditioning peripheral blood stem cell allogeneic transplantation. Oncotarget. 2018;9:11451–11464. doi:10.18632/oncotarget.24328
   PubMedGoogle Scholar
• Foley B, Cooley S, Verneris MR, et al. NK cell education after allogeneic transplantation: dissociation between recovery of cytokine-producing and cytotoxic functions. Blood. 2011;118:2784–2792. doi:10.1182/blood-2011-04-347070
   PubMed Web of Science ®Google Scholar
• Fehniger TA, Cooper MA, Nuovo GJ, et al. CD56bright natural killer cells are present in human lymph nodes and are activated by T cell-derived IL-2: a potential new link between adaptive and innate immunity. Blood. 2003;101:3052–3057. doi:10.1182/blood-2002-09-2876
   PubMed Web of Science ®Google Scholar
• Ferlazzo G, Thomas D, Lin SL, et al. The abundant NK cells in human secondary lymphoid tissues require activation to express killer cell Ig-like receptors and become cytolytic. J Immunol. 2004;172:1455–1462. doi:10.4049/jimmunol.172.3.1455
   PubMed Web of Science ®Google Scholar